
Autoimmune diseases encompass more than 80 health disorders and affect more than 24 million people in the US and an estimated one in ten people worldwide.1,2 To compound this problem, studies indicate that a rise in detected antinuclear antibodies, biomarkers of autoimmunity, may indicate a rise in the future development of autoimmune diseases.3 Rheumatoid arthritis, type 1 diabetes, psoriasis, multiple sclerosis, and inflammatory bowel disease are among the more common autoimmune diseases, and recent studies have reported that while autoimmune diseases are more prevalent among females,4 they may also disproportionately impact specific racial groups.5,6
While the direct economic cost of autoimmune disease in the US is difficult to determine,7 the National Institute of Allergy and Infectious Diseases has estimated that the annual cost to the healthcare system is more than $100 billion, not including the cost of uninsured individuals, which is estimated to be at least another $25 billion per year, according to the American Autoimmune Related Diseases Association.8 This may be a substantial underestimation of the economic burden, however. A 2022 report found that the estimated combined direct and indirect costs associated with just one autoimmune disorder in the US, multiple sclerosis, was $85.4 billion annually.9
Medications and Biologic Drugs
Medications and biologic drugs used in the management of autoimmune diseases attempt to control disease flares, limit inflammatory damage, and extend periods of remission. However, consistent results may not be seen in each patient, there may be potentially serious side effects, and higher financial costs have also been noted for some drug options.10,11 The goal of contemporary treatment for rheumatoid arthritis (RA), as an example, is to halt or slow the progression of the disease before joint damage occurs,10 and treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologic DMARDs in the early stages of RA is usually recommended.12 But not all patients respond to or tolerate DMARDs, and researchers continue to clarify associations between DMARDs and potential severe adverse health effects such as interstitial lung disease13 and dementia.14,15 What are the nonpharmaceutical, cost-effective treatment options that may help improve symptoms and quality of life for autoimmune disease patients?
Modifiable Lifestyle Factors: Nutrition and Exercise
Dietary patterns that promote the consumption of anti-inflammatory foods may help alleviate physiological biomarkers associated with inflammation16 and symptoms of chronic inflammatory conditions.17,18 A 2020 systematic review of randomized controlled trials found that as an adjunctive treatment, patients living with RA may turn to dietary interventions such as the Mediterranean diet to reduce systemic inflammation associated with their disease.19 In addition, a 2018 systematic review identified beneficial effects from following a Mediterranean diet in reducing pain and increasing physical function for those patients living with RA.20
Physical activity is proven safe and beneficial in most autoimmune diseases. A 2021 meta-analysis found that home-based physical activity interventions reduced autoimmune rheumatic disease symptoms and pain and improved functional capacity as well as quality of life for patients compared to controls.21 Another meta-analysis reported improvements in balance and functional walking ability for patients living with multiple sclerosis who engaged in exercise routines such as yoga, aerobic training, and aquatic exercise.22
Conclusion
While prescription medications remain at the forefront in the battle against autoimmune disease, researchers are identifying other treatment modalities to help improve patients’ quality of life. Functional medicine offers an alternative to symptom suppression—by addressing the underlying mechanisms that cause autoimmunity. Through collaborative therapeutic partnerships with patients and creating effective, personalized, and sustainable treatment and health strategies, functional medicine practitioners support the health journey for each individual patient.
At IFM’s upcoming Immune Functional Medicine Advanced Practice Module® (APM), learn more from functional medicine experts about autoimmune disorders and the clinical applications and lifestyle-based tools that help support immunity and health outcomes.
Related Topics

Hot Topic Feb 2025: Study Links Dietary Lignans With Reduced Risk of Mortality in Those With Type 2 Diabetes

Immune Fitness: Potential Barriers to Optimal Immune Responses

Strengthening Muscle to Benefit Cardiometabolic Health
REFERENCES
- Autoimmune diseases. National Institute of Environmental Health Sciences. Reviewed December 17, 2024. Accessed January 10, 2025. https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm
- Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-1890. doi:10.1016/S0140-6736(23)00457-9
- Dinse GE, Parks CG, Weinberg CR, et al. Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol. 2022;74(12):2032-2041. doi:10.1002/art.42330
- Goulmamine S, Chew S, Aninye IO. Autoimmune health crisis: an inclusive approach to addressing disparities in women in the United States. Int J Environ Res Public Health. 2024;21(10):1339. doi:10.3390/ijerph21101339
- Roberts MH, Erdei E. Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race. Autoimmun Rev. 2020;19(1):102423. doi:10.1016/j.autrev.2019.102423
- Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73(6):991-996. doi:10.1002/art.41632
- Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. doi:10.1016/j.coi.2022.102266
- Blumberg RS, Dittel B, Hafler D, von Herrath M, Nestle FO. Unraveling the autoimmune translational research process layer by layer. Nat Med. 2012;18(1):35-41. doi:10.1038/nm.2632
- Bebo B, Cintina I, LaRocca N, et al. The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs. Neurology. 2022;98(18):e1810-e1817. doi:10.1212/WNL.0000000000200150
- Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857. doi:10.3390/cells10112857
- Benjamin O, Goyal A, Lappin SL. Disease Modifying Anti-Rheumatic Drugs (DMARD). StatPearls Publishing; July 3, 2023. Accessed January 10, 2025. https://www.ncbi.nlm.nih.gov/books/NBK507863/
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi:10.1002/acr.24596
- Provan SA, Ljung L, Kristianslund EK, et al. Interstitial lung disease in patients with rheumatoid arthritis or psoriatic arthritis initiating biologics and controls: data from 5 Nordic registries. J Rheumatol. 2024;51(11):1111-1118. doi:10.3899/jrheum.2024-0252
- Chou MH, Wang JY, Lin CL, Chung WS. DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: a propensity score-matched case-control study. Toxicol Appl Pharmacol. 2017;334:217-222. doi:10.1016/j.taap.2017.09.014
- Xie W, Hou Y, Xiao S, Zhang X, Zhang Z. Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis. RMD Open. 2024;10(1):e004016. doi:10.1136/rmdopen-2023-004016
- Koelman L, Egea Rodrigues C, Aleksandrova K. Effects of dietary patterns on biomarkers of inflammation and immune responses: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2022;13(1):101-115. doi:10.1093/advances/nmab086
- Field R, Pourkazemi F, Turton J, Rooney K. Dietary interventions are beneficial for patients with chronic pain: a systematic review with meta-analysis. Pain Med. 2021;22(3):694-714. doi:10.1093/pm/pnaa378
- Schönenberger KA, Schüpfer AC, Gloy VL, et al. Effect of anti-inflammatory diets on pain in rheumatoid arthritis: a systematic review and meta-analysis. Nutrients. 2021;13(12):4221. doi:10.3390/nu13124221
- Nelson J, Sjöblom H, Gjertsson I, Ulven SM, Lindqvist HM, Bärebring L. Do interventions with diet or dietary supplements reduce the disease activity score in rheumatoid arthritis? A systematic review of randomized controlled trials. Nutrients. 2020;12(10):2991. doi:10.3390/nu12102991
- Forsyth C, Kouvari M, D'Cunha NM, et al. The effects of the Mediterranean diet on rheumatoid arthritis prevention and treatment: a systematic review of human prospective studies. Rheumatol Int. 2018;38(5):737‐747. doi:10.1007/s00296-017-3912-1
- Sieczkowska SM, Smaira FI, Mazzolani BC, Gualano B, Roschel H, Peçanha T. Efficacy of home-based physical activity interventions in patients with autoimmune rheumatic diseases: a systematic review and meta-analysis. Semin Arthritis Rheum. 2021;51(3):576-587. doi:10.1016/j.semarthrit.2021.04.004
- Hao Z, Zhang X, Chen P. Effects of different exercise therapies on balance function and functional walking ability in multiple sclerosis disease patients—a network meta-analysis of randomized controlled trials. Int J Environ Res Public Health. 2022;19(12):7175. doi:10.3390/ijerph19127175